Back to News
Market Impact: 0.2
Voyager Therapeutics Reports Third Quarter 2026 Financial Results and $132 Million Cash Position
Source: Nasdaq
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Voyager Therapeutics reported third-quarter results for the period ended September 30, 2026, and had $132.1 million in cash, cash equivalents, and marketable securities at quarter-end. The company said those funds should be sufficient to fund planned operations; the provided excerpt ends before specifying the funding period or other results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens